These findings are in line with the report of Brem and colleagues, who stated that obatoclax, a BH3 mimetic that can specifically target and counteract Bcl-2 family proteins, results in increased cell death via an autophagy-mediated pathway in rituximab-resistant DLBCL cells [47]. Here, BCL2 is linked to diffuse large B-cell lymphoma.